Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

NINLARO

×

Overview

What is NINLARO?

NINLARO (ixazomib) is an antineoplastic agent. Ixazomib citrate, a prodrug, rapidly hydrolyzes under physiological conditions to its biologically active form, ixazomib. The chemical name of ixazomib citrate is 1,3,2-dioxaborolane-4,4-diacetic acid, 2-[(1)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo- and the structural formula is:

The molecular formula for ixazomib citrate is CHBClNOand its molecular weight is 517.12. Ixazomib citrate has one chiral center and is the R-stereoisomer. The solubility of ixazomib citrate in 0.1N HCl (pH 1.2) at 37°C is 0.61 mg/mL (reported as ixazomib). The solubility increases as the pH increases.

NINLARO (ixazomib) capsules for oral use contain 4, 3 or 2.3 mg of ixazomib equivalent to 5.7, 4.3 or 3.3 mg of ixazomib citrate, respectively. Inactive ingredients include microcrystalline cellulose, magnesium stearate, and talc. Capsule shells contain gelatin and titanium dioxide. The 4 mg capsule shell contains red and yellow iron oxide, the 3 mg capsule shell contains black iron oxide and the 2.3 mg capsule shell contains red iron oxide. The printing ink contains shellac, propylene glycol, potassium hydroxide, and black iron oxide.



What does NINLARO look like?



What are the available doses of NINLARO?

Capsules: 4 mg, 3 mg, and 2.3 mg ()

What should I talk to my health care provider before I take NINLARO?

How should I use NINLARO?

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Recommended starting dose of 4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle. ()

Dose should be taken at least one hour before or at least two hours after food. ()


What interacts with NINLARO?

Sorry No Records found


What are the warnings of NINLARO?

Sorry No Records found


What are the precautions of NINLARO?

Sorry No Records found


What are the side effects of NINLARO?

Sorry No records found


What should I look out for while using NINLARO?

None.


What might happen if I take too much NINLARO?

There is no known specific antidote for NINLARO overdose. In the event of an overdose, monitor the patient for adverse reactions [] and provide appropriate supportive care.


How should I store and handle NINLARO?

NINLARO is cytotoxic. Capsules should not be opened or crushed. Direct contact with the capsule contents should be avoided. In case of capsule breakage, avoid direct contact of capsule contents with the skin or eyes. If contact occurs with the skin, wash thoroughly with soap and water. If contact occurs with the eyes, flush thoroughly with water.Any unused medicinal product or waste material should be disposed in accordance with local requirements.NINLARO is cytotoxic. Capsules should not be opened or crushed. Direct contact with the capsule contents should be avoided. In case of capsule breakage, avoid direct contact of capsule contents with the skin or eyes. If contact occurs with the skin, wash thoroughly with soap and water. If contact occurs with the eyes, flush thoroughly with water.Any unused medicinal product or waste material should be disposed in accordance with local requirements.Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12Quinapril tablets, USP are supplied as follows:5 mg tablets18NDC 63304-548-30NDC 63304-548-90NDC 63304-548-1010 mg tabletsRX549NDC 63304-549-30NDC 63304-549-90NDC 63304-549-1020 mg tabletsRX550NDC 63304-550-30 NDC 63304-550-90NDC 63304-550-1040 mg tabletsRX551NDC 63304-551-30NDC 63304-551-90NDC 63304-551-10Dispense in well-closed containers as defined in the USP.Protect from light.Store at controlled room temperature, 20 to 25º C (68 to 77º F) with excursions permitted between 15 to 30º C (59 to 86º F). (See USP).To report SUSPECTED ADVERSE REACTIONS, contact the FDA at or . Manufactured for:Ranbaxy Pharmaceuticals Inc.Jacksonville, FL 32257 USAOctober 2015 FDA-12


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.

Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse multiple myeloma tumor xenograft model.

Non-Clinical Toxicology
None.

Thrombocytopenia has been reported with NINLARO with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle. Three percent of patients in the NINLARO regimen and 1% of patients in the placebo regimen had a platelet count ≤ 10,000/mmduring treatment. Less than 1% of patients in both regimens had a platelet count ≤ 5000/mm during treatment. Discontinuations due to thrombocytopenia were similar in both regimens (< 1% of patients in the NINLARO regimen and 2% of patients in the placebo regimen discontinued one or more of the three drugs).The rate of platelet transfusions was 6% in the NINLARO regimen and 5% in the placebo regimen.

Monitor platelet counts at least monthly during treatment with NINLARO. Consider more frequent monitoring during the first three cycles. Manage thrombocytopenia with dose modifications [] and platelet transfusions as per standard medical guidelines.

The following adverse reactions are described in detail in other sections of the prescribing information:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).